Patel Anish's Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Jan 10, 2025
- Accession no.
- 0001415889-25-001301
- Filed
- Jan 10, 2025
- Trade date
- Jan 7, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 3 derivative transactions. Open-market sales total $685.8K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Patel AnishCIK 0001967163 | Officer (CHIEF OPERATING OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 7, 2025 | Common Stock | MOption exerciseAcquired | +10,700 | $1.12 | +$11,984 | 10,700 | Direct | |
| Jan 7, 2025 | Common Stock | MOption exerciseAcquired | +2,000 | $2.48 | +$4,960 | 12,700 | Direct | |
| Jan 7, 2025 | Common Stock | MOption exerciseAcquired | +9,000 | $2.48 | +$22,320 | 21,700 | Direct | |
| Jan 7, 2025 | Common Stock | SSaleDisposed | −20,260 | $24.15F2 | −$489,279 | 1,440 | Direct | |
| Jan 7, 2025 | Common Stock | SSaleDisposed | −1,440 | $24.56F3 | −$35,366.4 | 0 | Direct | |
| Jan 7, 2025 | Common Stock | SSaleDisposed | −6,577 | $24.17F4 | −$158,966.09 | 336,734 | Indirect | |
| Jan 7, 2025 | Common Stock | SSaleDisposed | −90 | $24.60F6 | −$2,214 | 336,644 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 7, 2025 | Common Stock | MOption exerciseDisposed | −10,700 | $0.00 | $0 | 67 | Direct | |
| Jan 7, 2025 | Common Stock | MOption exerciseDisposed | −2,000 | $0.00 | $0 | 827 | Direct | |
| Jan 7, 2025 | Common Stock | MOption exerciseDisposed | −9,000 | $0.00 | $0 | 44,342 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $23.5364 to $24.535. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $24.54 to $24.63. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $23.595 to $24.585. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades at prices ranging from $24.60 to $24.61. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.